In order to assess the efficacy of mebendazole against ADPKD-relevant phenotypes in vivo, we utilised the P18 iKsp-Pkd1del mouse model, which employs a tamoxifen-inducible cadherin promoter to selectively disrupt Pkd1 expression in the kidney epithelium at postnatal day (PND) 18, and has previously been employed to evaluate new therapeutic strategies (Dagorn et al., 2023; Song et al., 2023). Here, PKD1 is linked to autosomal dominant polycystic kidney disease.